Morgan Stanley lowered the firm’s price target on Pfizer (PFE) to $28 from $32 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Ideaya Biosciences completes enrollment in OptimUM-02 trial
- Pfizer announces results from HER2CLIMB-05 trial
- Pfizer price target raised to $29 from $28 at HSBC
- Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk
- FDA probe into COVID vaccines includes adults, Bloomberg reports